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Abstract
Background—Health-care personnel (HCP) are at risk for exposure to and possible transmission 
of vaccine-preventable diseases. Receiving recommended vaccines is an essential prevention 
practice for HCP to protect themselves and their patients. The tetanus, diphtheria and acellular 
pertussis vaccine (Tdap) was recommended by the Advisory Committee on Immunization 
Practices (ACIP) for HCP in 2006 for protection against pertussis. We assessed the recent 
compliance of U.S. HCP in receiving Tdap vaccination.
Methods—To estimate Tdap vaccination coverage among HCP, we analyzed data from the 2011 
National Health Interview Survey (NHIS). Multivariable logistic regression and predictive 
marginal models were performed to identify factors independently associated with vaccination 
among HCP.
Results—Overall, Tdap vaccination coverage was 26.9% among HCP aged 18-64 years (95% 
confidence interval (CI)=24.3%, 29.7%), which was significantly higher compared with non-HCP 
among the same age group (11.1%; 10.5%–11.8%). Overall, vaccination coverage was 
significantly higher among physicians (41.5%) compared with nurses (36.5%) and other types of 
HCP (range 11.7% to 29.9%). Vaccination coverage was significantly higher among HCP aged 
18-49 years compared with those 50-64 years (30.0% vs. 19.2%, respectively). Characteristics 
independently associated with an increased likelihood of Tdap vaccination among HCP were: 
younger age, higher education, living in the western United States, being hospitalized within past 
year, having a place for routine health care in clinic or health center, and receipt of influenza 
vaccination in the previous year. Marital status of widowed, divorced, or separated was 
independently associated with a decreased likelihood of Tdap vaccination among HCP.
Conclusions—By 2011, Tdap vaccination coverage was only 26.9% among HCP. Vaccination 
coverage varied widely by types of HCP and demographic characteristics. Emphasizing the 
Correspondence and requests for reprints should be sent to: Peng-jun Lu, National Center for Immunization and Respiratory Diseases, 
Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mail Stop A‐19, Atlanta, GA 30333, lhp8@cdc.gov. 
Disclaimer: The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of CDC.
Conflict of Interest Statement:
All authors have no conflicts of interest to be stated.
HHS Public Access
Author manuscript
Vaccine. Author manuscript; available in PMC 2018 February 22.
Published in final edited form as:
Vaccine. 2014 January 23; 32(5): 572–578. doi:10.1016/j.vaccine.2013.11.077.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
benefits of HCP vaccination for staff and patients, providing vaccinations in the workplace and 
other non-traditional settings, and providing Tdap at no charge may help increase Tdap 
vaccination among HCP in all health-care settings.
Keywords
Tetanus; diphtheria and acellular pertussis vaccine (Tdap); vaccination; coverage; health-care 
personnel
Introduction
Healthcare personnel (HCP) may work (paid or unpaid) in settings with potential for 
exposure to patients and/or to infectious materials. HCP with such exposures include 
physicians, nurses, nursing assistants, therapists, technicians, emergency medical service 
personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students 
and trainees, and persons not directly involved in patient care but potentially exposed to 
infectious agents that can be transmitted to and from HCP and patients.1–2 HCP are at 
increased risk for acquiring pertussis infection as a result of contact with infected patients 
and waning protection from either childhood pertussis vaccination or prior pertussis 
infection.2–5 Healthcare-associated outbreaks of pertussis have been reported in healthcare 
facilities.6–8 About 8.5%–23% of HCP were infected with pertussis during these outbreaks.
6–8
 Infected HCP can serve as sources of infection for susceptible contacts, including 
patients, other HCP, and family members.9–16
Vaccination offers the best protection against pertussis infection in HCP and in adults, in 
general.10–16 In 2006, the Advisory Committee on Immunization Practices (ACIP) 
recommended that HCP aged 19–64 years receive a single dose of the tetanus, diphtheria, 
and acellular pertussis vaccine (Tdap) to reduce the risk of transmission of pertussis in 
healthcare institutions.15 In 2010, ACIP updated HCP recommendations indicating that all 
HCP regardless of age should receive a single dose of Tdap as soon as feasible if they have 
not previously received Tdap.2 Vaccinating HCP with Tdap can be a cost-effective strategy 
to prevent outbreaks in healthcare setting.11–15
We used data from the 2011 National Health Interview Survey (NHIS) to assess Tdap 
vaccination and identify factors independently associated with vaccination among HCP in 
the United States.
Methods
We analyzed data from the 2011 National Health Interview Survey (NHIS) to assess Tdap 
vaccination among HCP. The NHIS is an annual household survey for the U.S. non-
institutionalized, civilian population conducted by the National Center for Health Statistics 
of the Centers for Disease Control and Prevention.17 Estimates were weighted to the adult 
civilian population of the United States. Face to face interviews were conducted each week 
throughout the year in a probability sample of households. In the sample adult core, one 
adult per sampled family was randomly selected and asked to complete the sample adult 
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questionnaire. The study sample consisted of 25,823 adults aged 18-64 years. In 2011, the 
final response rate for the sample adult core was 66.3%.17
To determine Tdap vaccination status, respondents were asked “Have you received a tetanus 
shot in the past 10 years?” Respondents who answered “yes” were asked “Was your most 
recent tetanus shot given in 2005 or later?” An affirmative answer to this question prompted 
another question “Did the doctor tell you the vaccine included the pertussis or whooping 
cough vaccine?” Respondents without “yes” or “no” responses for the above three questions 
were excluded from the assessment of Tdap vaccination. Sensitivity calculations were 
conducted to assess the magnitude of potential bias, assuming all excluded respondents were 
either 1) not vaccinated or 2) vaccinated.
Healthcare personnel were defined as persons who answered “yes” to the following 
question: “Do you currently volunteer or work in a hospital, medical clinic, doctor’s office, 
dentist’s office, nursing home or some other health-care facility? This includes part-time and 
unpaid work in a health care facility as well as professional nursing care provided in the 
home”. The following question was asked regarding direct patient care: “Do you provide 
direct patient care as part of your routine work?” For this analysis, HCP included those 
reporting they did or did not provide direct patient care.
Among 2,455 HCP 18-64 years, Tdap vaccination status could be assessed for 1,769 
respondents. Excluded were HCP without a “yes” or no” classification for tetanus 
vaccination status within the preceding 10 years (n=60 [2.4%]) and HCP without a tetanus 
vaccination status during 2005-2011 (n=86 [3.5%]) or those reported tetanus vaccination 
during 2005-2011 but were not told vaccine type by the provider (n=468 [19.0%] or did not 
know vaccine type (Td, or Tdap) (n=72 [2.9%]). Among 23,368 non-HCP 18-64 years, Tdap 
vaccination status could be assessed for 15,893 respondents. Excluded were non-HCP 
without a “yes” or no” classification for tetanus vaccination status within the preceding 10 
years (n=807 [3.5%]), for tetanus vaccination status during 2005-2011 (n=732 [3.1%]), or 
those who reported tetanus vaccination during 2005-2011, but were not told vaccine type by 
the provider (n=5117 [21.9%]) or did not know vaccine type (Td, or Tdap) (n=820 [3.5%]).
We used SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, 
NC) to calculate point estimates and 95% confidence intervals (CIs) of vaccination coverage.
18
 HCP who reported a tetanus vaccination during 2005-2011, but were unable to say 
whether Td or Tdap was used, were excluded from the analysis. All analyses were weighted 
to reflect the age, sex, and race/ethnicity of the U.S. non-institutionalized, civilian 
population. Bi-variable analysis was conducted using a Pearson’s χ2 to test population 
distributions between HCP and non HCP. We used t-tests to test the difference in vaccination 
coverage by HCP status and within each demographic and other characteristic category. 
Statistical significance was defined as p<0.05. The adjusted risk ratio or prevalence ratio, 
based on the predictive marginal under multivariable logistic regression model, was used to 
identify factors independently associated with vaccination among HCP. The risk ratio or 
prevalence ratio is a direct measure of effect when outcomes are not rare. Separate full 
multivariable logistic regression models for HCP and non-HCP were used to determine 
adjusted prevalence ratio of Tdap vaccination by selected demographic and access to care 
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variables. Multivariable logistic regression models were conducted both ways (with 
influenza vaccination status in the model and without influenza vaccination status in the 
model) to check whether influenza vaccination status could change the outcome of the 
model.
Sensitivity analyses were conducted to evaluate the magnitude of potential recall bias for 
Tdap on the vaccination coverage estimate and factors associated with vaccination.
Results
Of the 25,823 adults, 9.3% (2,455) were HCP. Demographic characteristics of the study 
population are given in Table 1. The majority of HCP were 18-49 years (70.7%), female 
(71.8%), white (68.4%), married (56.2%), had a college education or higher (79.1%), were 
living at or above poverty (92.0%), had a place for routine health care (92.3%), and had 
health insurance (86.4%). Except for age group and hospitalization status, HCP differed 
significantly from non-HCP for all other characteristics.
Among those for whom vaccination status could be identified, Tdap vaccination coverage 
among HCP was 26.9% (95% confidence interval (CI)=24.3%, 29.7%), significantly higher 
than among non-HCP (11.1%) (Table 2). Tdap vaccination coverage was significantly higher 
among HCP compared with coverage among non-HCP across all subgroups except those 
reporting other race or ethnicity (Table 2). Tdap vaccination coverage was 29.6% (26.3%, 
33.2%) among HCP with direct patient contact, which was significantly higher compared to 
HCP without direct patient contact (21.8%; 17.7%, 26.5%)
In bi-variable analysis, Tdap vaccination coverage was significantly higher among HCP 
18-49 years (30.0%) compared to HCP 50-64 years (19.2%) (Table 2). Tdap vaccination 
coverage among HCP was significantly higher among persons who reported having higher 
education, living at or above poverty level, living in the western United States, having 
greater number of physician contacts in the past year, hospitalized within past year, having a 
clinic/health center or doctor’s office/HMO as the usual place for health care, having health 
insurance, and having received influenza vaccination in the previous year (Table 2). Tdap 
vaccination coverage among HCP was significantly lower among persons who reported 
being widowed, divorced, or separated (Table 2).
In multivariable analysis, characteristics independently associated with an increased 
likelihood of Tdap among HCP were: younger age, higher education, living in the western 
United States, having been hospitalized within past year, having a clinic or health center as 
the usual place for health care, and receipt of influenza vaccination in the previous year 
(Table 3). Model results did not change whether influenza vaccination was included or not 
(data not shown in the Table). Marital status of widowed, divorced, or separated was 
independently associated with a decreased likelihood of Tdap vaccination among HCP. 
Characteristics independently associated with an increased likelihood of Tdap among non-
HCP were: younger age, never married, higher education, living in the western United 
States, born in the United States, living with an infant aged<1 year, having greater number of 
physician contacts in the past year, having a clinic or health center or a doctor’s office/
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Health Maintenance Organization (HMO) as the usual place for health care, and receipt of 
influenza vaccination in the previous year (Table 3).
Tdap vaccination coverage was 41.5% (29.9%, 54.2%) for physicians, 36.5% (30.5%, 
43.0%) for nurses, 29.9% (21.8%, 39.5%) for other healthcare support occupations, 27.0% 
(19.9%, 35.5%) for other non-physician/nurse practitioners, 25.1% (18.3%, 33.4%) for other 
health technologists, 13.9% (10.5%, 18.2%) for nursing, psychiatric and home health aids, 
and 11.7% (4.8%, 25.9%) for clinical laboratory staff (Table 4).
Depending on what proportion of excluded respondents actually received Tdap, the 
sensitivity analysis showed that actual Tdap coverage among HCP could fall within the 
range of 20.3% to 44.8%. Sensitivity analyses showed that actual Tdap coverage among 
non-HCP could fall within the range of 8.0% to 35.9% depending on what proportion of 
excluded respondents actually received Tdap. Factors associated with Tdap vaccination 
slightly changed when multivariable models were conducted using upper level of coverage 
(44.8% for HCP, 35.9% for non-HCP) as the outcome variable based on sensitivity analyses. 
Factors associated with Tdap vaccination did not change when multivariable models were 
conducted using lower level of coverage (20.3% for HCP, 8.0% for non-HCP) as the 
outcome variable based on sensitivity analyses.
Discussion
Healthcare personnel are recommended to receive Tdap vaccination to protect themselves, 
their patients, and their families.1, 2 While HCP were more likely to be vaccinated with Tdap 
than those who were non-HCP, even among HCP, only about 1 in 4 HCP (26.9%) reported 
receiving Tdap vaccination. HCP with direct patient contact reported higher coverage 
(29.6%) than those without direct patient care (21.8%). Vaccination coverage varied widely 
by types of HCP and demographic characteristics.
Reported Tdap vaccination coverage among HCP is suboptimal. Influenza and Hepatitis B 
(HepB) vaccines are two other vaccines recommended for HCP in the United States.2, 19, 20 
Influenza vaccination coverage among HCP has ranged from 53.0% to 64.0% based on the 
2011 NHIS (CDC unpublished data), the 2007 National Immunization Survey-Adult, and a 
2011 HCP internet panel survey.19, 20 HepB coverage among HCP has ranged from 63% to 
70% based on the 2007 National Immunization Survey-Adult, and the 2010 NHIS.20, 21 
These estimates were higher compared with the 2011 estimated Tdap vaccination coverage 
among HCP. Influenza and HepB vaccination, however, have been recommended for HCP 
since 1984 and 1982, respectively, compared with Tdap which has been recommended for 
HCP only since 2006.15, 19, 21 Other factors, such as perceived risk and targeted vaccination 
campaigns, may also contribute to higher influenza and HepB vaccination among HCP.19–21 
Since Tdap vaccination coverage was first assessed in the United States in 2008,22 Tdap 
coverage among HCP has increased from 15.9% in 200820, 21 to 26.9% in 2011. Continued 
monitoring of Tdap vaccination among HCP is useful for evaluating vaccination campaigns, 
for planning, and to control pertussis among HCP and their contacts.
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Suboptimal Tdap coverage may in part be due to lower awareness of Tdap vaccine. One 
study showed that only 19% of individuals in the general population and about 39% of HCP 
reported having ever heard of Tdap vaccine.23 Additionally, the intent to receive Tdap 
vaccination is also low among HCP. One study indicated that only 13% of the respondents 
reported they planned to receive the vaccine.24 Intent to receive Tdap was low among all 
HCP occupational groups, including physicians (22%), nurses (9%), nursing aides (18%), 
therapists (14%), persons with other occupations (14%), technicians and persons with other 
healthcare support occupations (12%), and nurse practitioners and physician assistants 
(11%).24 Additional education of HCP about the benefits of vaccination might help increase 
vaccination coverage. Confusion about the interval to receive Tdap after receipt of the last 
Td vaccination might also have affected Tdap uptake among HCP. Not all HCP were 
instructed to get Tdap on a shortened interval: the 2006 ACIP recommendation stated that 
HCP who have direct patient contact should receive a single dose of Tdap as soon as 
feasible, with an interval as short as 2 years from the last dose of Td. HCP without direct 
patient contact were recommended to receive a single dose of Tdap to replace the next 
scheduled Td vaccination according to the routine recommendation at an interval no greater 
than 10 years since the last Td vaccination (15). ACIP recently (2011) recommended use of 
Tdap regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine.16
Several characteristics were associated with Tdap vaccination coverage. As seen in other 
studies, age, education, and marital status were associated with vaccination.20, 22, 23, 25 
Reported receipt of influenza vaccination in the past year among HCP was also associated 
with Tdap vaccination. Receipt of influenza vaccination in the past year may be a reflection 
of health seeking behavior and acceptance of or access to vaccinations or preventive services 
in general.25 Annual influenza vaccination among HCP in work settings could provide a 
platform for delivering Tdap vaccine and thus may help increase Tdap vaccination coverage 
among HCP.
We found that Tdap vaccination coverage among HCP who reported a clinic or health center 
as the place they usually go to for health care or had been hospitalized in the past 12 months 
was significantly higher than those who did not have a place they usually go for health care 
or had not been hospitalized in the past 12 months, even after controlling for other 
demographic and access-to-care factors. Having contact with a physician plays an important 
role in vaccination uptake.13, 14 Routine provider contacts or hospitalization can provide 
important opportunities for providers to recommend and vaccinate HCP to improve Tdap 
vaccination coverage. However, one study showed that the most common reason given by 
HCP who did not plan to receive Tdap vaccine is that their provider did not recommend the 
vaccine to them.24 Healthcare providers should take advantage of opportunities to 
recommend and vaccinate their patients when they access the medical system.
Living in the western United States was independently associated with a higher Tdap 
vaccination coverage among HCP. This result may reflect the percentage of hospital 
requirements for Tdap vaccination of HCP by region. One study indicated that about 31% of 
U.S. hospitals required HCP to receive Tdap vaccine and this percentage varied significantly 
by region.26 The percentage of hospitals requiring HCP to receive Tdap vaccine was 22.5% 
in the Midwest, 27.8% in the Northeast, 30.1% in the South, and 47.4% in the West. The 
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percentage of hospitals in the western United States requiring HCP to receive Tdap vaccine 
was significantly higher compared with other regions.26 In addition, our study indicated that 
vaccination coverage was higher in hospital settings, which is consistent with another study 
indicating that influenza vaccination coverage was higher in hospital settings as well.20
A comprehensive employer vaccination program including education about the benefits of 
vaccination, convenient access to vaccination services, the provision of Tdap vaccination at 
no charge, and vaccination requirements may help improve vaccination coverage.2, 15, 27–29 
Institutional requirements for influenza vaccination have led to higher vaccination levels.27 
One study examined influenza vaccination coverage following institution of vaccination 
policies, within a sample of U.S. hospitals, and found that single season influenza 
vaccination rates increased approximately 15% after institution of hospital policies requiring 
receipt of influenza vaccination.27 Policies requiring vaccination with Tdap vaccine have 
also improved vaccination levels.28, 29 In 2010, the University of North Carolina made 
employment of HCP with direct patient contact conditional upon Tdap vaccination. After 
implementation of the policy, a nearly 100% compliance rate was achieved.29 Hospitals and 
other healthcare institutions should consider providing vaccination at no or minimal cost to 
their employees and should consider policies to encourage vaccination.
The findings in this report are subject to several limitations. First, vaccination coverage was 
self-reported and therefore might be subject to recall bias. No studies have evaluated the 
validity of self-reported Tdap vaccination among HCP. Self-reported influenza and 
pneumococcal vaccination status among adults have been shown to be fairly sensitive and 
specific.30–33 Second, many respondents were excluded from estimations of Tdap coverage, 
creating a potential for bias. HCP who reported a tetanus vaccination during 2005-2011, but 
were unable to say whether Td or Tdap was used, were excluded. Sensitivity analyses were 
conducted to evaluate the magnitude of potential bias. Depending on what proportion of 
excluded respondents actually received Tdap, actual self-reported Tdap coverage among 
HCP could fall within the range of 20.3% to 44.8%. Based on our study, the percentages of 
respondents who reported unknown vaccine type were lower among HCP compared to non-
HCP. Since vaccination is based on self-report and HCP have greater awareness of Tdap and 
Td differences and less likely to report unknown vaccine type, and thus might yield a higher 
coverage among HCP compared to non-HCP. Finally, confusion with Td and changes in 
ACIP recommendations since 2006 may affect the accuracy of self-reported Tdap 
vaccination coverage and thus future studies in terms of validity of Tdap vaccination are 
necessary.2, 15
Tdap vaccination among HCP is crucial to minimize risk of pertussis infection among HCP, 
their patients, and their families. Despite the availability of a safe and effective vaccine, 
Tdap vaccination coverage among HCP was low (26.9%). Comprehensive strategies are 
needed to further improve uptake of Tdap vaccination coverage for HCP. Recommended 
approaches include: emphasizing the benefits of HCP vaccination for staff and patients; 
considering the level of vaccination coverage among HCP to be one measure of patient 
safety and quality assurance; electronic tracking of coverage levels by ward, unit, and 
occupation; providing vaccinations in the workplace and free of charges; identifying where 
vaccination coverage levels are low and using the information to target interventions; 
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developing comprehensive health care workplace infectious control programs that include 
pertussis control and address Tdap vaccination of HCP; and implementing catch-up 
vaccination programs for HCP who are already employed and ensuring that newly hired 
HCP receive necessary vaccinations.2, 34–36 Any comprehensive strategy needs to be tailored 
to the needs of the health care institution to improve coverage and protect HCP, their 
patients, and their families.
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TABLE 2
Tdap vaccination coverage by healthcare personnel status, demographic and access-to-care variables among 
persons 18-64 years in the United States, NHIS 2011
Healthcare personnel Non healthcare personnel
Characteristic % (95% CI) % (95% CI) p-Value*
Total 26.9 (24.3-29.7) 11.1 (10.5-11.8) <0.001
Age
18-49 30.0 (26.8-33.5)† 12.3 (11.4-13.2)† <0.001
50-64‡ 19.2 (15.4-23.7) 8.5 (7.7-9.5) <0.001
Sex
Male‡ 26.4 (21.2-32.4) 9.9 (9.0-10.8) <0.001
Female 27.1 (24.2-30.2) 12.4 (11.5-13.4)† <0.001
Race/ethnicity
Non-hispanic White‡ 27.4 (24.2-30.8) 12.5 (11.6-13.4) <0.001
Non-hispanic Black 22.1 (16.8-28.5) 10.0 (8.5-11.6)† <0.001
Hispanic 29.8 (22.5-38.3) 6.4 (5.4-7.6)† <0.001
Asian 27.6 (19.0-38.2) 9.6 (7.6-12.1)† <0.001
Other 31.2 (16.9-50.4) 18.4 (13.7-24.4)† 0.155
Marital Status
Married‡ 28.9 (25.4-32.6) 11.2 (10.3-12.1) <0.001
Widowed/divorced/separated 16.9 (12.4-22.6)† 8.6 (7.3-10.1)† 0.001
Never married 27.9 (23.4-32.9) 12.1 (10.9-13.3) <0.001
Education
High school or less‡ 16.3 (11.8-22.2) 8.3 (7.4-9.3) 0.003
Some college or college graduate 28.3 (25.1-31.7)† 12.8 (11.8-13.7)† <0.001
Above college graduate 34.3 (27.9-41.3)† 15.1 (13.0-17.4)† <0.001
Poverty level
At or above poverty 27.7 (24.9-30.7)† 11.6 (10.9-12.5) <0.001
Below poverty‡ 20.0 (13.6-28.3) 10.1 (8.7-11.6) 0.001
Region
Northeast‡ 21.8 (16.6-28.1) 9.7 (8.2-11.6) <0.001
Midwest 25.2 (20.7-30.2) 12.1 (10.6-13.7)† <0.001
South 26.2 (22.2-30.7) 10.0 (8.9-11.3) <0.001
West 35.4 (28.4-43.1)† 12.9 (11.6-14.2)† <0.001
US Born
Yes 27.5 (24.6-30.6) 12.3 (11.5-13.1)† <0.001
No‡ 23.6 (18.3-29.9) 6.4 (5.4-7.6) <0.001
Living with an infant aged<1 year
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Healthcare personnel Non healthcare personnel
Characteristic % (95% CI) % (95% CI) p-Value*
Yes 31.8 (18.6-48.8) 20.6 (17.0-24.8)† 0.167
No‡ 26.7 (24.0-29.6) 10.7 (10.1-11.4) <0.001
Physician contacts within past year
None‡ 14.9 (10.4-20.7) 6.3 (5.4-7.5) 0.002
1 25.2 (20.0-31.4)† 9.5 (8.3-11.0)† <0.001
2-3 30.0 (25.6-34.8)† 11.9 (10.7-13.1)† <0.001
4-9 28.8 (23.6-34.7)† 14.4 (12.9-16.1)† <0.001
≥10 31.6 (24.6-39.7)† 16.9 (14.7-19.5)† <0.001
Hospitalization within past year
Yes 39.0 (29.3-49.6)† 17.7 (14.8-20.9)† <0.001
No‡ 26.0 (23.3-29.0) 10.6 (9.9-11.3) <0.001
Usual place for health care
Clinic or health center 33.1 (27.1-39.8)† 12.6 (11.3-14.2)† <0.001
Doctor’s office or HMO§ 27.0 (24.0-30.2)† 12.1 (11.2-13.1)† <0.001
Some other place 30.4 (17.4-47.5) 8.9 (6.6-12.0)† 0.008
None‡ 13.5 (8.9-20.1) 5.6 (4.5-6.9) 0.006
Health insurance
Yes 28.1 (25.3-31.2)† 12.4 (11.6-13.2)† <0.001
No‡ 18.7 (13.4-25.4) 6.9 (5.9-8.1) <0.001
Influenza vaccination, past year
Yes 34.4 (30.8-38.2)† 18.5 (17.0-20.2)† <0.001
No‡ 17.7 (14.5-21.4) 8.3 (7.7-9.0) <0.001
*p value by t test for comparisons between healthcare personnel and non-healthcare personnel within each level of each characteristic.
†p<0.05 by t test for comparisons within each variable with the indicated reference level.
‡
Reference level.
§
Health maintenance organization.
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TABLE 4
Tdap vaccination coverage by types of healthcare personnel and facilities among persons 18-64 years in the 
United States, NHIS 2011
Occupations
Ambulatory health 
care services % (95% 
CI)
Hospitals % (95% 
CI)
Nursing and 
residential care 
facilities % (95% 
CI) Total % (95% CI)
Total 25.5 (21.6-30.0) 35.2 (29.9-40.9) 14.3 (9.7-20.5) 27.3 (24.4-30.4)
Physicians 31.4 (18.7-47.8) 58.6 (37.3-77.2) 41.5 (29.9-54.2)
Nurses 39.8 (28.7-52.0) 38.3 (30.8-46.5) 18.7 (8.2-37.0) 36.5 (30.5-43.0)
Others in non-physician/nurse 
practitioners group* 24.6 (16.2-35.4) 36.1 (21.1-54.4) † 27.0 (19.9-35.5)
Clinical laboratory † † † 11.7 (4.8-25.9)‡
Health technologists§ 23.1 (14.0-35.6) 31.8 (20.6-45.7) 12.2 (3.0-38.3) 25.1 (18.3-33.4)
Nursing, psychiatric, and home health 
aids 11.1 (6.8-17.8)‡ 20.3 (12.0-32.2)‡ † 13.9 (10.5-18.2)‡
Healthcare support occupations‖ 29.3 (20.2-40.5) 35.5 (18.2-57.5) † 29.9 (21.8-39.5)
*
Including chiropractors, dentists, dietitians and nutritionists, optometrists, pharmacists, physician assistants, podiatrists, audiologists, occupational 
therapists, physical therapists, radiation therapists, respiratory therapists, etc.
†
Estimates are not reliable due to sample size is less than 30.
‡p<0.05 by t test for comparisons within each healthcare setting with physicians as the reference level.
§
Including dental hygienists, diagnostic related technologists and technicians, emergency medical technicians and paramedics, health diagnosing 
treating practitioner support technicians, medical records and health information technicians, opticians, dispensing, etc.
‖
Including occupational therapist assistants and aides, physical therapist assistants, massage therapists, dental assistants, medical assistants, etc.
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